MedTrace Logo

Intracerebroventricular Tralesinidase Alfa in Children With Mucopolysaccharidosis Type IIIB

NCT07579910 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-05-12

No results posted yet for this study

Summary

The primary objectives of this study are to evaluate the effects of Tralesinidase Alfa (TA) on cognition

Conditions

  • MPS IIIB

Interventions

DRUG

Tralesinidase alfa (TA)

TA study drug is a sterile solution for ICV infusion.

Sponsors & Collaborators

  • Spruce Biosciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-31
Primary Completion
2033-08-31
Completion
2033-08-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07579910 on ClinicalTrials.gov